Onkologi

An alliance between Clínica Medilaser and the Instituto Médico Oncológico has consolidated an integrated program to treat central nervous system tumors in southern Colombia. The service, led by neurosurgeon Silvia Quintero, serves patients from several regions from its Neiva site.

Selasa, 05 Mei 2026 Dilaporkan oleh AI

One month after the nationwide oncology sanitary alert took effect, Health Minister May Chomali led the signing of a decree transferring $154 billion from the Ministry of Hacienda to the Ministry of Health (Minsal). The funds will exclusively support the Oncology Alert Plan, enhancing public health services' capacity to resolve oncology waiting lists affecting thousands of patients.

Servier Egypt has launched Tibsovo (ivosidenib), the first targeted therapy available in the country for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and intrahepatic cholangiocarcinoma. The treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data. It is approved as a first-line treatment for AML and a second-line option for intrahepatic cholangiocarcinoma.

Sabtu, 22 November 2025 Dilaporkan oleh AI

Oncologist Paulo Hoff warned that excessive sun exposure is the most common cause of cancer, particularly non-melanoma skin cancer. In a course on CasaFolha, he emphasizes the importance of prevention and early diagnosis to boost cure rates. Hoff recommends avoiding the sun between 10am and 2pm and using sunscreen.

Kombinasi enzalutamide dan terapi hormon telah mengurangi risiko kematian lebih dari 40% pada pria dengan kanker prostat yang kambuh, menurut uji klinis besar. Studi yang melibatkan lebih dari 1.000 pasien di seluruh dunia ini dipimpin oleh peneliti di Cedars-Sinai dan dipresentasikan di kongres medis di Berlin. Para ahli menggambarkan temuan ini sebagai perubahan permainan untuk mengobati kasus agresif.

Jumat, 03 Oktober 2025 Dilaporkan oleh AI

Researchers at Spain's National Cancer Research Centre (CNIO) have developed a comprehensive catalog of mutational 'scars' in DNA caused by cancer. This breakthrough, published in Nature, could help bypass resistances to treatments like PARP inhibitors. The study analyzes thousands of tumor samples to identify key genetic patterns.